Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study

BACKGROUND: Daclizumab is a humanized monoclonal antibody against CD25 that modulates interleukin 2 signaling. The SELECT TRILOGY of clinical studies (SELECT/SELECTION/SELECTED) evaluated the safety and efficacy of daclizumab in patients with relapsing-remitting multiple sclerosis (RRMS). We report...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :BMC Neurol
Главные авторы: Gold, Ralf, Radue, Ernst-Wilhelm, Giovannoni, Gavin, Selmaj, Krzysztof, Havrdova, Eva, Stefoski, Dusan, Sprenger, Till, Montalban, Xavier, Cohan, Stanley, Umans, Kimberly, Greenberg, Steven J., Ozen, Gulden, Elkins, Jacob
Формат: Artigo
Язык:Inglês
Опубликовано: BioMed Central 2016
Предметы:
Research Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4962457/
https://ncbi.nlm.nih.gov/pubmed/27461166
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12883-016-0635-y
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы